Showcases Stock ranks Forex

Sorrento Therpt (SRNE)
9.28  -0.36 (-3.73%) 01-25 16:00
Open: 9.51 Pre. Close: 9.64
High: 9.7 Low: 8.7644
Volume: 20,553,839 Market Cap: 2,540M
Sorrento Therapeutics, Inc., a clinical stage biopharma company, develops therapies for cancer, autoimmune, inflammatory, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches. It also offers Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. In addition, the company's clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft-versus-host diseases. Further, it develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. Additionally, the company engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain conditions. It has various collaborations with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 86 patients with COVID-19; and Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection, as well as a research testing agreement with The University of Texas Medical Branch at Galveston for the preclinical testing of Sorrento's COVID-19 therapeutic product candidates. The company was founded in 2006 and is based in San Diego, California.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 9.711 - 9.79 9.79 - 9.843
Low: 8.608 - 8.689 8.689 - 8.743
Close: 9.169 - 9.3 9.3 - 9.389
Stock Technical Analysis
Target: Six months: 12.59
One year: 14.71
Support: Support1: 8.18
Support2: 6.58
Resistance: Resistance1: 10.78
Resistance2: 12.59
Pivot: 8.25
Moving Averages: MA(5): 9.67
MA(20): 8.00
MA(100): 8.15
MA(250): 6.29
MACD: MACD(12,26): 0.57
Signal(12,26,9): 0.33
%K %D: %K(14,3): 72.70
%D(3): 76.11
RSI: RSI(14): 60.88
52-Week: High: 19.39
Low: 1.55
Change(%): 129.1
Average Vol(K): 3-Month: 1552980
10-Days: 2151102
Price, MAs and Bollinger Bands
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.

SRNE has closed below upper band by 28.0%. Bollinger Bands are 34.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
Stock chart
Stock News
Tue, 22 Dec 2020
Sorrento Announces It Has Submitted An Emergency Use Authorization (EUA) Application to the FDA for COVI-STIX™ Rapid Test for the Detection of SARS-CoV-2 Viral Antigen - GlobeNewswire

Tue, 08 Dec 2020
Sorrento Receives Licensure From the State of California for Clinical Testing Laboratory (CLIA) Allowing for Clinical Sample Testing - GlobeNewswire

Sun, 29 Nov 2020
Sorrento to Participate in the 32nd Piper Sandler Healthcare Investor Conference - GlobeNewswire

Fri, 09 Oct 2020
Sorrento COVID-19 R&D October 13, 2020 Pipeline Call Details Released - GlobeNewswire

Sun, 04 Oct 2020
Sorrento to Host a R&D Day to Showcase COVID-19 Product Pipeline - GlobeNewswire

Wed, 12 Aug 2020
Sorrento to Take Action Against Hindenburg Research for Statements Believed Intended to Manipulate Stock Price - GlobeNewswire

Financial Analysis
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company's ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Stock Basics & Statistics
Exchange:  NASDAQ Capital Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 273.70
Shares Float (M) 198.53
% Held by Insiders 15.71
% Held by Institutions 27.97
Shares Short (K) 68980
Shares Short Prior Month (K) 75390
Stock Financials
EPS -1.500
Book Value (p.s.) 0.810
Profit Margin
Operating Margin -428.52
Return on Assets (ttm) -19.1
Return on Equity (ttm) -409.0
Qtrly Rev. Growth 103.4
Gross Profit (p.s.) -0.320
Sales Per Share 0.152
EBITDA (p.s.) -0.608
Qtrly Earnings Growth
Operating Cash Flow (M) -154.69
Levered Free Cash Flow (M) -141.04
Stock Valuation
PE Ratio -6.19
PEG Ratio
Price to Book value 11.46
Price to Sales 61.17
Price to Cash Flow -16.42
Stock Dividends
Dividend Yield
Dividend Growth

Stoxline Lite

Stoxline Pro

Stock Chart

Option Calculator